Wall Street Is Sleeping on This Fintech Giant—Here’s Why It Could Double
Despite fast growth, high profitability and an extraordinary runway ahead, Nu Holdings (NYSE:NU)’s share price is down almost 24% in the last month as stock markets have sold off in response to weaker economic conditions in the US in 2025. This leaves the question of whether NU could be a good buy today for long-term gains. » Read more about: Wall Street Is Sleeping on This Fintech Giant—Here’s Why It Could Double »
Read More
1 Sports Apparel Stock Set To Keep Soaring?
Few investors know that sports apparel giant, Lululemon Athletica, was originally founded as a design studio by day and yoga studio by night. Fast forward to today, and the company is nothing short of a global phenomenon that last week made it into the S&P 500 club.
But what’s on the horizon now for this extraordinary apparel firm?
» Read more about: 1 Sports Apparel Stock Set To Keep Soaring? »
Read More
Market Commentary: What’s Inside Buffett’s Portfolio?
In its latest 13F filing, Berkshire Hathaway bought and sold some stocks that paint a clear picture of what Buffett thinks the future of the economy will look like. Some old favorites he left untouched while others he sold off with abandon. Yet other stocks, he accumulated in spades.
What is Buffett buying and selling now?
» Read more about: Market Commentary: What’s Inside Buffett’s Portfolio? »
Read More
Market Commentary: The Meteoric Rise of Eli Lilly
Did you know that Eli Lilly and other pharmaceutical companies have sold approximately 10.6 million shots of obesity drug doses in the U.S. in a single month? The rise of these injectable weight loss medications is so powerful that it’s causing investors to question the future of even staple food and beverage stocks.
While this aspect alone could secure Eli Lilly as the pharmaceutical golden goose you’ve been looking for there is much more than meets the eye.
» Read more about: Market Commentary: The Meteoric Rise of Eli Lilly »
Read More
Is This $1.4B Cybersecurity Giant Just Getting Started?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has seen its share price soar by more than 30 percent in the last 12 months alone.
With a growing portfolio of security solutions, it seems like the future is bright but has all the good news been priced in?
» Read more about: Is This $1.4B Cybersecurity Giant Just Getting Started? »
Read MoreThe Ivy
Which AI Stock Is Best?
The artificial intelligence gold rush has created winners and wannabes. Two companies at the center of that storm, C3.ai and CoreWeave, have taken very different paths in the race to capitalize on enterprise AI demand. Both play crucial roles in the AI stack, one builds the software brains, the other supplies the computational muscle. But only one of them has the market’s full attention.
» Read more about: Which AI Stock Is Best? »
Read MoreThe Spotlight
1 Money-Making Stock Investors Are Sleeping On
ResMed might not be a household name for the average investor, but its portfolio of almost 6,000 patents focused on sleep apnea and respiratory care suggest perhaps it should be. The IP forms an economic moat for ResMed in the medical devices industry, which is massive.
One of the key factors attracting investors to ResMed is the booming sleep apnea devices market,
» Read more about: 1 Money-Making Stock Investors Are Sleeping On »
Read MoreThe Daily
Stock Market LIVE Updates: GIFT Nifty indicates a weak start; US, Asian markets slip
Indian equities are expected to open on a cautious to negative note on January 19, with GIFT Nifty indicating a start around 25,600, nearly 151 points lower. While near-term sentiment remains guarded, underlying domestic technical indicators continue to provide some support. That said, the broader market direction is likely to remain influenced by global equity cues,